ALSO NOTED: Indevus gains $50M payday; Genzyme settles suit; AnGes submits ERT; and much more...

> Indevus has snared a $49.9 million milestone payment following the FDA's approval of Sanctura XR. Release

> Genzyme has agreed to settle a shareholders suit for $64 million. Release

> Biomarin Pharmaceutical Japan-based partner AnGes MG has submitted enzyme replacement therapy Nagalzyme for approval to the Japanese Ministry of Health, Labour and Welfare, AnGes said. Release

> GeneNews has gained $2 million to develop prostate biomarkers. Release

> Ambit Biosciences has added 36 new kinases to its screening panel, including therapeutically relevant lipid, mutant, and atypical kinases. Release

> Australia has banned Novartis' Prexige. FiercePharma

> Just as predicted, Johnson & Johnson has found itself in the midst of a PR nightmare over its trademark dust-up with the American Red Cross. FiercePharma

And Finally... A bird flu outbreak has been reported on Bali. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.